Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
AXA-1665 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 August 2026
AXA-1665: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
SYS6017Y Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 August 2026
SYS6017Y: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
BMN-351 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 August 2026
BMN-351: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Novel oral poliomyelitis vaccine type 1(nOPV1)(PATH) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 August 2026
Novel oral poliomyelitis vaccine type 1(nOPV1)(PATH): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals.
8 min read
AZD-8965 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 August 2026
AZD-8965: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
TL-938 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 August 2026
TL-938: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Fecal microbiota transplantation (Human Biome) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 August 2026
Fecal microbiota transplantation (Human Biome): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals.
8 min read
BPR-101 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 August 2026
BPR-101: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
AAPB Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 August 2026
AAPB: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
MAX-10181 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 August 2026
MAX-10181: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
AK146D1 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 August 2026
AK146D1: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
BI-1819479 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 August 2026
BI-1819479: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.